Biogen Idec/Elan Tysabri Guaranteed Coverage Under Medicare Part B
Executive Summary
Biogen Idec/Elan's once-monthly I.V. formulation of the multiple sclerosis therapy Tysabri guarantees that the product will be covered under Medicare Part B
You may also be interested in...
Tysabri May Launch At Higher Price With Added Efficacy Data, RiskMAP Cost
Biogen Idec/Elan appear poised to market their re-approved multiple sclerosis therapy Tysabri (natalizumab) at a higher price than when it was first introduced
Tysabri May Launch At Higher Price With Added Efficacy Data, RiskMAP Cost
Biogen Idec/Elan appear poised to market their re-approved multiple sclerosis therapy Tysabri (natalizumab) at a higher price than when it was first introduced
Biogen/Elan Tysabri Combination Use Higher Than Expected Since Launch
Demand for Biogen Idec/Elan's Tysabri for combination use with other multiple sclerosis therapies has been greater than expected in the product's first two months on the market